Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase
2 studies and a compassionate access study in which a regimen containing
once-daily Sovaldi® (sofosbuvir) 400 mg was administered for
the treatment of chronic hepatitis C virus (HCV) infection in patients
with advanced liver disease. These data are being presented this week at
the 49th Annual Meeting of the European Association for the Study of the
Liver (The International Liver Congress 2014) in London.
The first study, Study GS-US-334-0125 (Oral #068), is an ongoing
open-label Phase 2 clinical trial evaluating HCV patients with cirrhosis
and portal hypertension, with or without decompensation, who were
randomized 1:1 to an immediate treatment arm in which Sovaldi and
ribavirin (RBV) was administered for 48 weeks (n=25) or to a deferred
treatment arm in which this regimen was initiated after a 24-week
observation period (n=25). Eighty percent of participants were
Of the 22 patients who completed 24 weeks of therapy, 95 percent
(n=21/22) achieved virologic suppression on treatment. Additionally,
patients taking Sovaldi-based therapy experienced trends in clinical and
laboratory parameter improvements compared to patients in the
observation arm. Sovaldi-based therapy was well tolerated in the study,
and only one patient discontinued treatment due to an adverse event. The
most common adverse events occurring in more than 25 percent of patients
included nausea and pruritis. Patients in both arms of the study will be
followed to determine their 12-week sustained virologic response rates
(SVR12) after 48 weeks of Sovaldi-based therapy.
Study GS-US-334-0126 (Poster #1232), was a single-arm open-label Phase 2
trial in which patients with established recurrent HCV infection
following liver transplantation received up to 24 weeks of therapy with
Sovaldi plus RBV (escalating doses starting at 400 mg/day). The majority
of patients had genotype 1-HCV infection (n=33/40) and 88 percent
(n=35/40) were treatment-experienced.
Seventy percent (n=28/40) of patients in this study achieved SVR12. The
most common adverse events occurring in more than 20 percent of patients
were fatigue, headache, arthralgia (joint pain) and diarrhea. There were
no deaths, graft losses or episodes of organ rejection among post-liver
transplantation patients, and no drug-drug interactions were reported
between Sovaldi and immunosuppressive agents.
A third, compassionate access study (Oral #62), evaluated Sovaldi
therapy among 104 post-transplant patients with severe recurrent HCV,
including fibrosing cholestatic hepatitis, who had exhausted all other
treatment options and received pre-approval access to Sovaldi via
Gilead's compassionate use program. Patients received up to 48 weeks of
Sovaldi plus RBV, with some patients also receiving pegylated interferon
(peg-IFN) (180 µg/week) at their physician's discretion. The majority of
patients in the study experienced clinical improvements on treatment.
Overall, 62 percent of patients achieved SVR12. Sovaldi-based therapy
was well tolerated.
"The patients included in these analyses are historically among the most
difficult to cure, and many have had no appropriate treatment options
until now," said Norbert Bischofberger, PhD, Executive Vice President of
Research and Developmnt and Chief Scientific Officer, Gilead Sciences.
"These data demonstrate that Sovaldi-based oral therapy can improve
outcomes, has a favorable safety profile and is well tolerated among
hepatitis C patients with severe liver disease."
Additional information about Study GS-US-334-0125 and Study
GS-US-334-0126 can be found at www.clinicaltrials.gov.
Sovaldi is an oral nucleotide analog inhibitor of the HCV NS5B
polymerase enzyme, which plays an essential role in HCV replication.
Sovaldi is a direct-acting agent, meaning that it interferes directly
with the HCV life cycle by suppressing viral replication.
Sovaldi was approved in the United States on December 8, 2013
and in the European Union on January 17. In the United States, Sovaldi
is approved for the treatment of chronic hepatitis C infection as a
component of a combination antiviral treatment regimen. Efficacy has
been established in subjects with HCV genotype 1, 2, 3 or 4 infection,
including those with hepatocellular carcinoma meeting Milan criteria
(awaiting liver transplantation) and those with HCV/HIV-1 co-infection.
Treatment response varies based on baseline host and viral factors.
Monotherapy is not recommended for treatment of chronic hepatitis C.
Studies GS-US-334-0125 and GS-US-334-0126 evaluated investigational uses
of Sovaldi, for which safety and efficacy have not yet been established.
IMPORTANT SAFETY INFORMATION
Sovaldi combination treatment with ribavirin or with peginterferon alfa
plus ribavirin is contraindicated in women who are pregnant or may
become pregnant and men whose female partners are pregnant because of
the risk for birth defects and fetal death associated with ribavirin.
Contraindications to peginterferon alfa and ribavirin also apply to
Sovaldi combination treatment. Refer to the prescribing information of
peginterferon alfa and ribavirin for a list of their contraindications.
Warnings and Precautions
Most common (=20 percent, all grades) adverse reactions for:
In addition to rifampin and St. John's wort, coadministration of Sovaldi
is not recommended with carbamazepine, oxcarbazepine, phenobarbital,
phenytoin, rifabutin, rifapentine, and tipranavir/ritonavir. Such
coadministration is expected to decrease the concentration of
sofosbuvir, reducing its therapeutic effect.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company's mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
California, Gilead has operations in North and South America, Europe and
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors, including the
possibility of unfavorable longer-term results from clinical trials
evaluating Sovaldi for the treatment of HCV among patients with advanced
liver disease, and the risk that healthcare providers, payers or
insurers may not recognize the benefits of Sovaldi over other agents. As
Sovaldi is used over longer periods of time by treatment-experienced
patients with underlying health problems taking numerous other
medicines, Gilead may find new issues such as safety, resistance or drug
interaction issues, which may require it to provide additional warnings
or contraindications in the label, which could reduce the market
acceptance of Sovaldi. These risks, uncertainties and other factors
could cause actual results to differ materially from those referred to
in the forward-looking statements. The reader is cautioned not to rely
on these forward-looking statements. These and other risks are described
in detail in Gilead's Annual Report on Form 10-K for the year ended
December 31, 2013, as filed with the U.S. Securities and Exchange
Commission. All forward-looking statements are based on information
currently available to Gilead, and Gilead assumes no obligation to
update any such forward-looking statements.
U.S. full prescribing information for Sovaldi is available at www.gilead.com.
Sovaldi is a registered trademark of Gilead Sciences, Inc.
For more information on Gilead Sciences, please visit the company's
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
[ Back To NFVZone's Homepage ]